Tela Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

25 Mar 2026

TELA

10-K: TELA Bio Reports 16% Revenue Growth, $38.8M Net Loss in 2025

TELA Bio, a medical technology company, reported a 16% increase in revenue to $80.3 million for 2025, alongside a net loss of $38.8 million, as it expands its soft-tissue reconstruction product portfolio.

NASDAQ

21 Mar 2025

TELA

Tela Bio, INC

10-K: TELA Bio Reports 19% Revenue Increase in 2024, Driven by OviTex and OviTex PRS Sales

TELA Bio, Inc. announces a 19% increase in revenue for 2024, driven by growth in OviTex and OviTex PRS product sales, while reducing its net loss by 19%.

NASDAQ

22 Mar 2024

TELA

Tela Bio, INC

10-K: TELA Bio, Inc. Reports 41% Revenue Increase in 2023 Annual Filing

TELA Bio, Inc. reports a significant 41% revenue increase in its 2023 annual filing, driven by strong sales of its OviTex and OviTex PRS products.